Breast Cancer
Conditions
Brief summary
This project aims to investigate the role of MMA in breast cancer. To this end, we will measure MMA on serum samples collected at the time of breast cancer diagnosis, to investigate the role of MMA in predicting long-term recurrence risk, response to neoadjuvant chemotherapy, and its association with age and clinical frailty.
Detailed description
This project aims to investigate the role of MMA in breast cancer. To this end, we will measure MMA on serum samples collected at the time of breast cancer diagnosis, to investigate the role of MMA in predicting long-term recurrence risk, response to neoadjuvant chemotherapy, and its association with age and clinical frailty. If the role of baseline serum MMA in therapy resistance and/or metastasis is confirmed, our study could be further extended by evaluating SOX4 expression in the tumor tissues (SOX4 is activated by MMA, and SOX4 induces EMT (epithelial to mesenchymal transition) and the metastasis process.
Interventions
DIAGNOSTIC_TESTmethylmalonic acid testing
Sponsors
KU Leuven
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Inclusion criteria
1. Female patients older than 18 years at diagnosis. 2. First diagnosis of invasive breast cancer. 3. All pathological parameters are available to identify histological subtype according to standard procedures. 4. Availability of frozen serum samples at diagnosis. 5. Voluntarily signed Informed Consent obtained before blood drawing for biobanking was performed.
Exclusion criteria
1. Pregnant at diagnosis. 2. stage 0 disease (in situ). 3. Bilateral BC at diagnosis or multifocal unilateral BC with different histology. 4. Other subtypes than Invasive ductal carcinoma. 5. Prior breast cancer.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| MMA levels | baseline | baseline serum MMA levels in pre-defined patients |
Countries
Belgium
Outcome results
None listed